$9,567.92 consulting Payment -- AbbVie Inc to Dr. James Wilson

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

This report analyzes a payment of $9,567.92 made by AbbVie Inc. to Dr. James Wilson, an oncologist in City, AZ, on May 18, 2025. The payment was for consulting services related to the drug Farxiga. **What the Payment Was For:** Pharmaceutical companies often engage physicians as consultants to gain insights into drug development, clinical trial design, and market feedback. This payment likely compensated Dr. Wilson for his expertise and time in providing such advice to AbbVie regarding Farxiga. Oncology is a rapidly evolving field, and drug manufacturers rely on the practical experience of practicing oncologists to refine their products and strategies. **Typicality of the Amount:** For a consulting engagement in oncology, $9,567.92 is a substantial but not necessarily extraordinary amount. Consulting fees can vary widely based on the physician's expertise, the duration and scope of the consulting work, and the specific needs of the pharmaceutical company. Oncology specialists are in high demand for their knowledge, and their time is valuable, which can command higher consulting fees compared to some other specialties. **Potential Conflict of Interest:** Any financial relationship between a pharmaceutical company and a physician can raise questions about potential conflicts of interest. While consulting is a legitimate way for companies to gather expert opinions, it's important for patients to be aware that such payments exist. The core concern is whether a physician's prescribing decisions could be influenced by these financial ties, rather than solely by the best interests of the patient and the latest clinical evidence. Transparency through programs like the Sunshine Act aims to mitigate these concerns by making these relationships public. **Comparison to Industry Averages:** The Open Payments database reveals that payments to physicians are common across many specialties. Oncology physicians, due to the complexity and high cost of cancer treatments, often receive significant payments for various services, including consulting, speaking, and research. While this specific payment is above the average for all physicians, it may fall within a typical range for oncologists engaged in consulting for major pharmaceutical firms. **Patient Understanding:** It is crucial for patients to understand that physicians may have financial relationships with pharmaceutical companies. These relationships are not inherently unethical or illegal, and many serve legitimate purposes in advancing medical knowledge and drug development. However, patients should be empowered with this information to have open conversations with their doctors about their treatment plans and any potential influences on prescribing decisions. Awareness fosters trust and ensures that patient care remains the paramount consideration.

Patient Guidance: What This Payment Means for You

It's understandable to have questions when you see a payment like this. Remember, this payment doesn't automatically mean your doctor's decisions are compromised. Pharmaceutical companies pay doctors for their expertise, which can help improve drugs and treatments. However, it's wise to be informed. At your next appointment, you can ask your doctor directly: 'I saw on the Open Payments website that you received a consulting fee from AbbVie. Can you tell me more about that relationship and how it relates to my care?' A good doctor will be open and explain their involvement. Consider what this payment means for your treatment. Is Farxiga a medication you are considering or currently taking? If so, discuss with your doctor why it's the best option for you, and if there are other alternatives. Payments for consulting, especially for a specific drug, warrant a conversation about prescribing influences. However, many payments are for broader advisory roles or research, which are generally considered routine. The key is open communication and ensuring your treatment plan aligns with your health needs and the best available evidence.

Payment Context: Is This Amount Normal?

Oncology is a specialty where physicians often engage with pharmaceutical companies due to the complex and evolving nature of cancer treatments. Payments to oncologists for consulting, speaking, and research are relatively common. While the exact amount can vary significantly, a payment of nearly $10,000 for consulting is substantial but not unheard of within this specialty, reflecting the high demand for expert oncological advice.

Regulatory Context: Sunshine Act Requirements

The Sunshine Act, part of the Affordable Care Act, requires pharmaceutical and medical device companies to report payments and other transfers of value made to physicians and teaching hospitals. This specific payment, a consulting fee of $9,567.92, exceeds the reporting threshold and must be publicly disclosed. Such payments are subject to scrutiny to ensure transparency and to help identify potential conflicts of interest, though they are legal when properly reported.

Related Topics

This payment is related to the following healthcare transparency topics:

• pharma-payments
• oncology
• consulting-fees
• sunshine-act
• conflict-of-interest
• abbvie
• farxiga

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

Does my doctor take pharma money?

You can find out by searching the CMS Open Payments database online. This database publicly lists payments made by pharmaceutical and medical device companies to physicians and teaching hospitals. If your doctor's name appears, it means they have received payments. It's important to remember that receiving payments doesn't automatically mean there's a conflict of interest. Many payments are for legitimate services like consulting, research, or speaking engagements that contribute to medical advancement. However, awareness of these relationships is key to informed discussions about your care.

Should I worry about this payment?

A payment of $9,567.92 for consulting is a significant amount, and it's natural to consider its implications. For an oncologist, consulting fees can be a normal part of their professional activities, especially if they are providing valuable expertise to a company developing treatments like Farxiga. However, it does warrant a conversation. Ask your doctor about the nature of the consulting work and how it informs their practice. If the payment is directly tied to a drug you are prescribed, it's especially important to discuss why that drug is the best choice for you and if other options exist. Generally, routine payments for broad advice are less concerning than payments tied to specific drug promotion.

What types of pharma payments are most concerning?

Payments that raise the most concern are typically those that appear to directly influence prescribing habits without clear clinical justification. This can include large speaking fees for promotional events, substantial consulting fees for work that seems minimal, or payments tied to prescribing specific drugs. Payments for research, educational activities, or general consulting where the physician provides broad expertise are often considered less concerning, though transparency is always important. The key is to look at the amount, the nature of the service provided, and whether it directly relates to a treatment you are receiving.

How do I talk to my doctor about pharma relationships?

Start by being direct and respectful. You could say, 'I saw on the Open Payments website that you've received payments from pharmaceutical companies. I'd like to understand how these relationships might relate to my care.' Ask specific questions like, 'Can you tell me about the consulting work you do?' or 'How do you ensure your prescribing decisions are based solely on patient needs and clinical evidence?' A good doctor will welcome these questions and provide clear answers, reinforcing trust. Frame it as a desire to be an informed patient, not an accusation.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for doctors to accept payments from pharmaceutical and medical device companies, provided these relationships are transparent and comply with regulations. The Sunshine Act requires companies to report most payments made to physicians, including consulting fees, speaking fees, research grants, and travel reimbursements. These payments are legal as long as they are for legitimate services and are properly disclosed. The intent of the law is to provide transparency, allowing patients and the public to see these financial ties and consider them when evaluating healthcare decisions.

Does pharma money affect what my doctor prescribes?

Research suggests that financial relationships with pharmaceutical companies can influence prescribing patterns, though the extent varies. Doctors who receive payments may be more likely to prescribe the company's drugs, especially if the payments are tied to specific products. However, many physicians maintain that they can separate financial interests from clinical judgment. It's important to remember that doctors also receive valuable information from these companies about new treatments and research. The best approach is to have an open dialogue with your doctor about your treatment options and the rationale behind their choices.

How does this compare to other doctors in this specialty?

Oncology is a field where physicians often have financial relationships with pharmaceutical companies due to the high cost and complexity of cancer treatments. Payments for consulting, research, and speaking are common. While the average payment across all physicians might be lower, oncologists are more likely to receive payments, and the amounts can be substantial. A payment of nearly $10,000 for consulting, while significant, is not necessarily an outlier for an oncologist providing expert advice to a drug manufacturer. Many oncologists receive similar or even larger payments annually.

Related Reports

• View Dr. James Wilson's full payment report
• AbbVie Inc full spending report
• Browse all Oncology payments
• Browse all payments in Arizona
• Search for other payments